Page 35 - Read Online

Oquendo et al. J Transl Genet Genom 2021;5:89-111 https://dx.doi.org/10.20517/jtgg.2021.04 Page 107

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021

REFERENCES
1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Blood 2016;127:2375-90. DOI PubMed PMC
2. Kanellis G, Mollejo M, Montes-Moreno S, et al. Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals
characteristic clinico-pathological features. Haematologica 2010;95:1122-9. DOI PubMed PMC
3. Traverse-Glehen A, Baseggio L, Salles G, Coiffier B, Felman P, Berger F. Splenic diffuse red pulp small-B cell lymphoma: toward
the emergence of a new lymphoma entity. Discov Med 2012;13:253-65. PubMed
4. Xochelli A, Kalpadakis C, Gardiner A, et al. Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a
marginal-zone origin: is this a distinct entity? Blood 2014;123:1199-206. DOI PubMed
5. Merli M, Bianchi B, Bertù L, et al. Clonal B-cell lymphocytosis with mariginal-zone features: comparison with overt splenic
marginal-zone lymphomas in 77 patients from a monocentric series. Blood 2019;134:4017. DOI
6. Chacón JI, Mollejo M, Muñoz E, Algara P, Mateo M, Lopez L, et al. Splenic marginal zone lymphoma: clinical characteristics and
prognostic factors in a series of 60 patients. Blood 2002;100:1648-54. PubMed
7. Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and
therapeutic criteria. Leukemia 2008;22:487-95. DOI PubMed
8. Zucca E, Arcaini L, Buske C, et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Marginal zone
lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:17-29. DOI PubMed
9. Lumish M, Falchi L, Imber BS, Scordo M, von Keudell G, Joffe E. How we treat mature B-cell neoplasms (indolent B-cell
lymphomas). J Hematol Oncol 2021;14:5. DOI PubMed PMC
10. Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: from genetics to management. Blood 2016;127:2072-81. DOI
PubMed
11. Melo JV, Hegde U, Parreira A, Thompson I, Lampert IA, Catovsky D. Splenic B cell lymphoma with circulating villous
lymphocytes: differential diagnosis of B cell leukaemias with large spleens. J Clin Pathol 1987;40:642-51. DOI PubMed PMC
12. Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes: natural history and response to
therapy in 50 cases. Br J Haematol 1991;78:206-9. DOI PubMed
13. Schmid C, Kirkham N, Diss T, Isaacson PG. Splenic marginal zone cell lymphoma. Am J Surg Pathol 1992;16:455-66. DOI
PubMed
14. Baldini L, Fracchiolla N, Cro L, et al. Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal
zone origin. Blood 1994;84:270-8. PubMed
15. Zhu D, Oscier DG, Stevenson FK. Splenic lymphoma with villous lymphocytes involves B cells with extensively mutated Ig heavy
chain variable region genes. Blood 1995;85:1603-7. PubMed
16. Mollejo M, Menárguez J, Lloret E, et al. Splenic marginal zone lymphoma: a distinctive type of low-grade B-cell lymphoma. A
clinicopathological study of 13 cases. Am J Surg Pathol 1995;19:1146-57. PubMed
17. Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C
virus infection. N Engl J Med 2002;347:89-94. DOI PubMed
18. Novak U, Rinaldi A, Kwee I, et al. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and
genomic deletions in marginal zone lymphomas. Blood 2009;113:4918-21. DOI PubMed PMC
19. Oscier DG, Matutes E, Gardiner A, et al. Cytogenetic studies in splenic lymphoma with villous lymphocytes. Br J Haematol
1993;85:487-91. DOI PubMed
20. Bikos V, Darzentas N, Hadzidimitriou A, et al. Over 30% of patients with splenic marginal zone lymphoma express the same
immunoglobulin heavy variable gene: ontogenetic implications. Leukemia 2012;26:1638-46. DOI PubMed
21. Xochelli A, Bikos V, Polychronidou E, et al. Disease-biased and shared characteristics of the immunoglobulin gene repertoires in
marginal zone B cell lymphoproliferations. J Pathol 2019;247:416-21. DOI PubMed
22. Bikos V, Karypidou M, Stalika E, et al. An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone
Lymphoma Expressing IGHV1-2*04 Receptors. Clin Cancer Res 2016;22:2032-40. DOI PubMed
23. Clipson A, Wang M, de Leval L, et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and